New data on safety and efficacy of Pradaxa < sup > ® < /sup > in treatment of acute deep vein thrombosis and pulmonary embolism
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
Benefits of Pradaxa < sup > ® < /sup > maintained in difficult to treat patients with atrial fibrillation and symptomatic heart failure
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
Boehringer Ingelheim announces comprehensive settlement of U.S. Pradaxa < sup > ® < /sup > (dabigatran etexilate) litigation
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
New data show dabigatran-specific antidote idarucizumab* restores blood clotting mechanism in humans
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
Pradaxa < sup > ® < /sup > gains EU approval for treatment and prevention of recurrence of deep vein thrombosis and pulmonary embolism
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
New data show specific antidote idarucizumab* reverses dabigatran-induced anticoagulation also in elderly and renally impaired volunteers
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
New Pradaxa < sup > ® < /sup > clinical study to explore practical management of patients with atrial fibrillation undergoing ablation
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
Effectiveness and Safety of NOACs vs. Warfarin in AFEffectiveness and Safety of NOACs vs. Warfarin in AF
How does the effectiveness and safety of dabigatran, rivaroxaban, and apixaban compare with warfarin when used for patients with atrial fibrillation in a routine care setting? British Medical Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 1, 2016 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
Predicting Adverse Events With Dabigatran or Warfarin in AFPredicting Adverse Events With Dabigatran or Warfarin in AF
This study examined various models that aim to quantify expected rates of thromboembolism and major bleeding for a given patient if that patient were to initiate treatment with dabigatran or warfarin British Medical Journal (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - June 10, 2016 Category: Intensive Care Tags: Internal Medicine Journal Article Source Type: news
With First Trials On Horizon, Value Of Growing Philly Xarelto Claims Uncertain
It might be more than a year from now, but litigation centered on the blood thinner Xarelto could eventually come to trial in Philadelphia courtrooms – and one attorney says the thousands of cases filed over the similar drug Pradaxa may serve as a guide to the value of those claims. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - May 20, 2016 Category: Pharmaceuticals Authors: Legal Newsline Source Type: news
Interim Phase III Data Show Praxbind® (idarucizumab) Reverses Dabigatran (Pradaxa®) in Emergency Situations
• A single 5g dose of idarucizumab immediately reversed the anticoagulant effect of dabigatran in all patients evaluated• Results based on analyses of high-risk patients from RE-VERSE AD™ study• Data presented at ACC 2016 Scientific Session and Expo (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 3, 2016 Category: Research Source Type: news
Interim Phase III Data Show Praxbind® (idarucizumab) Reverses Dabigatran (Pradaxa®) in Emergency Situations
• A single 5g dose of idarucizumab immediately reversed the anticoagulant effect of dabigatran in all patients evaluated • Results based on analyses of high-risk patients from RE-VERSE AD™ study • Data presented today at ACC 2016 Scientific Session and Expo (Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - April 1, 2016 Category: Research Source Type: news
Boehringer Ingelheim launches RE-COVERY DVT/PE™: global observational study on management of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) with Pradaxa® (dabigatran etexilate)
Boehringer Ingelheim today announces the enrollment of the first patient in RE-COVERY DVT/PE™, a global observational study on the management of blood clots in the legs (deep vein thrombosis, DVT) and in the lungs (pulmonary embolism, PE). (Source: World Pharma News)
Source: World Pharma News - March 24, 2016 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news
Idarucizumab may reverse dabigatran anticoagulation in intracranial hemorrhage
LOS ANGELES – It only took a few minutes for idarucizumab to normalize blood-clotting parameters in 18 patients with dabigatran-associated intracranial hemorrhages, according to interim results from... (Source: Clinical Neurology News)
Source: Clinical Neurology News - March 23, 2016 Category: Neurology Source Type: news
Idarucizumab may reverse dabigatran anticoagulation in intracranial hemorrhage
LOS ANGELES – It only took a few minutes for idarucizumab to normalize blood-clotting parameters in 18 patients with dabigatran-associated intracranial hemorrhages, according to interim results from... (Source: Family Practice News)
Source: Family Practice News - March 23, 2016 Category: Primary Care Source Type: news
